Ineke van Rossum, MD, Receives 2013 Alzheimer Award
July 1, 2013
Ineke van Rossum, MD, has been chosen as the recipient of the 2013 Alzheimer Award presented by the Journal of Alzheimer’s Disease in recognition of her outstanding work that implicates a different role for biomarkers in the diagnosis and prognosis of subjects with mild cognitive impairment due to Alzheimer’s disease.
“It is a great honor to have been chosen as the recipient of this year’s Journal of Alzheimer’s Disease award. We are very happy to notice that the article is appreciated by international colleagues in the Alzheimer research field,” said Ineke A. van Rossum, Alzheimer Center and Neurology Department of the VU University Medical Center, Amsterdam, The Netherlands.
Each year the more than 500 Associate Editors of the Journal of Alzheimer’s Disease vote to select an outstanding article published the previous year to receive this prestigious award, which is made possible by support from IOS Press. I.A. van Rossum will be presented with the bronze Alzheimer Medal featuring the likeness of Alois Alzheimer. The winning paper is entitled, “Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer’s Disease” (J Alzheimers Dis 29, 319-327, 2012), by I.A. van Rossum et al.
Biomarkers of amyloid pathology and neuronal injury in cerebrospinal fluid and on MRI scan can predict Alzheimer’s disease (AD) in subjects with mild cognitive impairment (MCI). However, the rate of progression from MCI to AD-type dementia is variable making prognosis for subjects with MCI uncertain. In this study van Rossum et al. confirmed the previous finding that both amyloid and injury markers can predict progression from MCI to AD-type dementia. A new finding was that in a selection of subjects with MCI who all progressed to AD-type dementia, only the injury markers but not amyloid markers predicted rapid cognitive decline. These findings implicate a different role for biomarkers in the diagnosis and prognosis of subjects with MCI due to AD. While amyloid markers can be used to diagnose the disease in an early stage, injury markers may be suitable for predicting further progression of the disease.
Ineke A. van Rossum, MD, studied Medicine at the University of Amsterdam in the Netherlands. From March 2009 to April 2013, she worked as a PhD student at the Alzheimer Center of the VU University Medical Center in Amsterdam. Under the supervision of Dr. Pieter Jelle Visser and Prof. dr. Philip Scheltens, she studied the use of cerebrospinal fluid and MRI biomarkers for the diagnosis and prognosis of Alzheimer’s disease in subjects with MCI. In April 2013 she started her specialist registrar training at the Neurology Department of the VU University Medical Center.
# # #
NOTES FOR EDITORS
Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer’s Disease. Ineke A. van Rossum, Pieter Jelle Visser, Dirk L. Knol, Wiesje M. van der Flier, Charlotte E. Teunissen, Frederik Barkhof, Marinus A. Blankenstein and Philip Scheltens. Journal of Alzheimer’s Disease 29(2), 319-327, 2012, DOI: 10.3233/JAD-2011-111694. Published by IOS Press.
Journalists wishing to interview I.A. van Rossum should contact Caroline Arps at the communications department VU University Medical Center, +31 20 444 3444 or firstname.lastname@example.org.
ABOUT THE JOURNAL OF ALZHEIMER’S DISEASE
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes. The Journal of Alzheimer’s Disease has an Impact Factor of 4.174 according to Thomson Reuters’ 2012 Journal Citation Reports. It is ranked #23 on the Index Copernicus Top 100 Journal List. The Journal is published by IOS Press.
ABOUT IOS PRESS
Commencing its publishing activities in 1987, IOS Press serves the information needs of scientific and medical communities worldwide. IOS Press now publishes more than 100 international journals and approximately 120 book titles each year on subjects ranging from computer sciences and mathematics to medicine and the natural sciences.
Headquartered in Amsterdam with satellite offices in the USA, Germany and China, IOS Press continues its rapid growth, embracing new technologies for the timely dissemination of information. All journals and books are available electronically.
George Perry, PhD
Editor-in-Chief, Journal of Alzheimer’s Disease
University of Texas at San Antonio
Tel: +1 210 458 4450
Fax:+1 210 458 4445
Tel: +31 20 688 3355
Fax: +31 20 687 0019